Brentuximab vedotin and Bendamustine Therapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Brentuximab vedotin and Bendamustine Therapy, 2019, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/529-brentuximab-vedotin-and-bendamustine-therapy.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL). | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Bendamustine, Brentuximab Vedotin |